10-Q: Y-mAbs Therapeutics Reports Q1 2025 Financial Results, Highlights DANYELZA Sales and R&D Progress

Y-mAbs Therapeutics' Q1 2025 results show increased revenue driven by international DANYELZA sales, alongside ongoing clinical trials and a business realignment strategy.

Summary

• Y-mAbs Therapeutics reported a net loss of $5.2 million for the three months ended March 31, 2025, compared to a net loss of $6.6 million for the same period in 2024.
• Net product revenue increased to $20.9 million from $19.4 million year-over-year, driven by growth in ex-U.S. markets.
• U.S. DANYELZA net product revenues decreased by 28% to $13.4 million, while ex-U.S. revenues increased significantly to $7.5 million.
• Cost of goods sold increased to $3.0 million from $2.1 million, reflecting higher sales volume in ex-U.S. regions with lower gross margins.
• Research and development expenses decreased to $11.4 million from $13.3 million, primarily due to timing of clinical trial completions and personnel cost reductions.
• Selling, general, and administrative expenses increased to $13.1 million from $11.4 million, driven by personnel costs, business realignment expenses, and legal fees.
• The company's business realignment plan, announced in January 2025, aims to optimize operations and accelerate clinical development within the radiopharmaceutical platform.
• Y-mAbs expects cash and cash equivalents of $60.3 million as of March 31, 2025, to be sufficient to fund operations into 2027.
• The company is evaluating GD2-SADA in an ongoing Phase 1 clinical trial, with the first patient dosed in April 2023.
• A Phase 2 clinical study in second line relapsed osteosarcoma patients with pulmonary-only recurrence and with complete surgical remission, has completed enrolment and is undergoing evaluation of results.
• The first patient was dosed in April 2025 in Phase I clinical trials targeting CD38-SADA in hematological tumors for patients with Relapsed or Refractory Non-Hodgkin Lymphoma.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss and a decrease in U.S. sales, there was significant growth in ex-U.S. sales and the company has a cash runway into 2027. The business realignment plan and ongoing clinical trials also suggest potential for future growth.

Positives

• Overall revenue increased year-over-year.
• Significant growth in ex-U.S. DANYELZA sales.
• Cash runway extended into 2027.
• Ongoing clinical trials for GD2-SADA and CD38-SADA.
• Business realignment expected to improve operational efficiency.
• Royalty revenue from distribution partners increased to $1.9 million from $0.5 million.

Negatives

• Net loss of $5.2 million for Q1 2025.
• U.S. DANYELZA sales decreased by 28%.
• Increased cost of goods sold due to higher ex-U.S. sales volume with lower gross margins.
• The company is expecting the cash payments related to the business realignment to continue into the first half year of 2026.
• The company expects that the manufacturer of the DANYELZA drug substance will transition the manufacturing from its facility in Greenville, North Carolina, to a facility in Monza, Italy and that no DANYELZA drug product will be manufactured from the date manufacturing ceases in Greenville, North Carolina, which is estimated to be in the second half of 2026, until the new facility becomes FDA approved to produce and begin production of the DANYELZA drug product.

Risks

• Reliance on third-party manufacturers for DANYELZA and product candidates.
• Uncertainties related to clinical trial outcomes and regulatory approvals.
• Competition from other biotechnology and pharmaceutical companies.
• Potential impact of healthcare reforms and pricing pressures.
• Risks associated with international operations, including tariffs and trade tensions.
• Potential business disruptions due to pandemics, geopolitical events, or natural disasters.
• The company is expecting the cash payments related to the business realignment to continue into the first half year of 2026.
• The company expects that the manufacturer of the DANYELZA drug substance will transition the manufacturing from its facility in Greenville, North Carolina, to a facility in Monza, Italy and that no DANYELZA drug product will be manufactured from the date manufacturing ceases in Greenville, North Carolina, which is estimated to be in the second half of 2026, until the new facility becomes FDA approved to produce and begin production of the DANYELZA drug product.

Future Outlook

Y-mAbs plans to advance its pipeline programs, initiate new research and pre-clinical development efforts, seek marketing approval for additional product candidates, and promote commercialization of approved products. The company estimates that its cash and cash equivalents will be sufficient to fund operations as currently planned into 2027.

Management Comments

• We intend to advance and expand our pipeline of therapeutic and diagnostic candidates into select adult and pediatric cancer indications either independently or in collaboration with potential partners.
• We believe SADA PRIT Technology could potentially improve the efficacy of immunological therapeutics, e.g., naked monoclonal antibodies, in tumors that have not historically demonstrated meaningful responses to immunological agents.

Industry Context

Y-mAbs operates in the competitive biotechnology and pharmaceutical industries, particularly in the cancer drug sector. The company faces competition from established pharmaceutical companies, academic research institutions, and other biotechnology firms developing immunotherapies and targeted therapies. The report highlights the company's efforts to differentiate itself through its proprietary radioimmunotherapy and antibody platforms.

Comparison to Industry Standards

• The report mentions competitors such as United Therapeutics Corporation, EUSA Pharma, and Renaissance Pharma Ltd in the GD2-positive tumor space.
• The company believes that the data supporting the use of DANYELZA for targeting GD2 is very compelling and worth further development.
• The SADA PRIT technology, which utilizes bispecific fusion proteins that bind to tumor cells before a radioactive payload is injected in a two-step approach, faces competition from a range of companies investigating antibody or antibody-fragment based development paradigms for comparable one-two-or-three step approaches.
• We believe our major competitors include Roche Sequencing Solutions, Clarity Pharmaceuticals, OncoOne Research & Development GmbH, Perspective Therapeutics, Curium SAS, Cellectar Biosciences, ITM Isotope Technologies Munich SE, Actinium Pharmaceuticals, Inc Lantheus , Blue Earth Therapeutics and Tagworks Pharmaceuticals which may change in the future.

Legal Proceedings

• The Company shall participate in the remaining appeal as a nominal party only, as it did in the underlying action and mediation.
• Plaintiff/Appellants appeal brief was filed on December 9, 2024.
• Mr. Gads brief was filed in March 2025 and Plaintiffs reply brief was filed on April 2, 2025.
• The Court has scheduled oral argument on the appeal on May 22, 2025.

Stakeholder Impact

• Shareholders: The report provides information on the company's financial performance and future prospects, which may influence investment decisions.
• Employees: The business realignment plan may impact employees, with potential workforce reductions.
• Customers: The report provides updates on the availability and commercialization of DANYELZA.
• Suppliers: The report discusses the company's reliance on third-party manufacturers and potential supply chain disruptions.
• Creditors: The report provides information on the company's liquidity and ability to meet its financial obligations.

Next Steps

• Advance development of pipeline programs.
• Initiate new research and pre-clinical development efforts.
• Seek marketing approval for additional product candidates.
• Promote commercialization of approved products.

Key Dates

Keywords

DANYELZA, Y-mAbs, Radioimmunotherapy, SADA PRIT, Clinical Trials, Neuroblastoma, RIT, Revenue, Financial Results, Oncology